Early-stage funding for European life sciences companies

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our current portfolio comprises of biotech developing truly disruptive solutions for high unmet medical needs.

Acerta, a multi-billion Euro success story

BioGeneration was co-founder and investor in the most successful biotech startup in Europe: Acerta Pharma. Acerta Pharma has developed Calquence® (acalabrutinib), a drug now approved by the FDA for the treatment of hematologic malignancies (leukemia). Acerta was sold to AstraZeneca for up to US$ 7 billion in 2016.

Shaping new life-science ventures

We gained our experience from working within small and large pharma and biotech companies. Based on this experience and through our extensive industry network, we are able to bring a range of sector-relevant expertise to help accelerate product development and shape the companies to become attractive investment opportunities for the industry.

Latest news

Synaffix Announces Expansion of Mersana License Deal to a Total Potential Value Exceeding $1 Billion

Nov 30, 2021

Expanded deal focuses on Synaffix’s GlycoConnect™ site-specific ADC bioconjugation technology and adds license options for six new programs to existing dealMersana currently developing two programs based on GlycoConnect™ site-specific ADC bioconjugation technology...

Confo Therapeutics Enters Collaborative Agreement with Regeneron

Nov 30, 2021

Confo will work together with Regeneron to apply its GPCR drug discovery platform to enable functional antibody discovery Ghent, Belgium – November 30, 2021 – Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron...

CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002 at SITC Conference

Nov 18, 2021

First four dose escalation levels completed showing excellent tolerability for CTL-002 as monotherapy and in combination with PD-1Preliminary pharmacodynamic analyses at early dose levels indicate CTL-002-mediated selective T cell shift into the tumor...

Icosabutate latest phase 2b interim data show significant decreases in NASH and fibrosis biomarkers independent of fibrosis stage and disease severity

Nov 16, 2021

Naarden, The Netherlands, 16 November 2021 – NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, today announces the presentation of new interim data from the Phase 2b...

News overview

Next events

19 – 21 October BioEntrepreneurship Summit 2021

Aug 27, 2021

At the BioEntrepreneurship Summit 2021, founders, startup enthusiasts, experienced entrepreneurs, corporates and investors will come together to foster the exchange of knowledge, to inspire and to empower, and to celebrate life science entrepreneurship. In 2021, the...

25-28 October – BioEurope

Jun 15, 2021

Building Partnerships in a Digital Age - Facilitating the flow of global life science deals. The international BIO-Europe® 2021 gathering will be held digitally, standing tall in this time of insecurity, to execute on its pivotal role in bringing the global biopharma...

25 November Dutch Life Sciences Conference

Aug 27, 2021

The 17th edition of the Dutch Life Sciences conference will take place on November 25th, 2021 and will be about "Breaking Barriers for Our Future." The COVID-19 pandemic has changed the world in many ways. The life sciences sector...

Event overview